FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and relates to an agent for treating conditions of cells of various organs and tissues, as well as human organs and tissues, associated with a decrease in IL-11 gene expression and/or a decrease in the amount of interleukin-11 protein based on gene therapeutic substances with the IL-11 gene, where the cells of organs and tissues are selected from fibroblast cells, uterine endometrium cells, chondrocytes and epithelial cells; organs and tissues are selected from the skin, uterus, cartilage tissue, endometrial tissue or human muscle tissue, which represents at least one gene-therapeutic substance selected from the group of gene-therapeutic substances, each of which represents a genetic construct based on a vector plasmid comprising the cDNA of the IL-11 gene, with the interleukin-11 protein coding sequence, with deletions of 5'- and 3'-nontranslated regions, namely, obtained from the site of the native unmodified cDNA of the IL-11 gene of SEQ ID No.: 1 or a region of the native unmodified cDNA of the IL-11 gene of SEQ ID No: 2 or a modified IL-11 gene cDNA, wherein the modified cDNA of the IL-11 gene uses SEQ ID No: 3, or SEQ ID No: 4, or SEQ ID No: 5, or SEQ ID No: 6, or SEQ ID No: 7, or a combination of these genetic constructs, each of which also contains regulatory elements in combination with or without a transport molecule. Group of inventions also relates to a method for producing said agent; a method of using said agent to treat conditions of the human body associated with a decrease in IL-11 gene expression and/or a decrease in the amount of interleukin-11 protein.
EFFECT: group of inventions provides a high and stable level of the target protein in the cells.
5 cl, 18 ex, 20 dwg
